跳至主要内容
临床试验/JPRN-jRCT1080222203
JPRN-jRCT1080222203已完成Unknown

esina tablets special drug use surveillance: Type 2 diabetes mellitus: monotherapy/combination therapy with alpha-GI

Takeda Pharmaceutical Company Limited0 个研究点目标入组 3,317 人开始时间: 2013年8月27日最近更新:

试验速览

阶段
Unknown
状态
已完成
入组人数
3,317

研究概览

简要总结

This survey was conducted to investigate the safety and efficacy of long-term use of Nesina in patients with inadequately controlled type 2 diabetes mellitus on diet and exercise therapies either alone or plus an alpha-GI. The survey results raised no major concerns about the safety or efficacy of long-term Nesina therapy.

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • Patients who have not adequately responded to any one of the following therapies:
  • (1) Diet and exercise therapy alone
  • (2) In addition to diet and exercise therapy, use of alpha-glucosidase inhibitor

排除标准

  • Patients contraindicated for Nesina
  • (1) Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus (these patients require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of Nesina is not appropriate.)
  • (2) Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury (blood glucose control by insulin injection is desirable for these patients, and hence use of Nesina is not appropriate.)
  • (3) Patients with a history of hypersensitivity to any ingredient of Nesina

研究者

相似试验